EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Amdocs Ltd (DOX) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Amdocs Ltd $119, price $58.36, upside +104.4%, quality 75 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Technology · US · Home United Kingdom · ISIN GB0022569080

AL Amdocs Ltd logo Broad data Sep 23, 2026

Amdocs Ltd

DOX · US

Strongly undervaluedStrong Fair Value upside with high Quality.

✓Fair value $119.31 · Strongly undervalued (+104%)
✓Quality 75/100
!Weak Growth (revenue 5y +1.7 %/yr)
✓Solidly profitable · 11.8% net margin (TTM)
✓Low debt · generates free cash flow
·3.68% dividend yield
✓Ranks above peers (12/15)
!Moderate moat 62/100
!Insider activity 40/100
!Weak on future: 20 out of 100
Watch Amdocs Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$91.51 $49.32 Fair Value $119.31 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $49.32 – $91.51 · fair‑value band $79.30 – $155.10 · the $58.36 price screens below the $119.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Amdocs in your weekly email

Every Wednesday you see whether Amdocs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Amdocs Limited, through its subsidiaries, provides software and services to communications, entertainment, media, and other service providers worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud offering.

Show more

Amdocs Limited, through its subsidiaries, provides software and services to communications, entertainment, media, and other service providers worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud offering. The company also provides CES25, a telco-native, GenAI-led customer experience suite, spanning business, and operations and network domains that is embedded with AI and related tools. In addition, it offers GenAI agents, and which include Customer Engagement Platform, a telecom-specific customer relationship management (CRM) solution; Amdocs Monetization Suite which enables customers to monetize their broad set of services and offerings; Amdocs Intelligent Networking Suite, a set of solutions that provide end-to-end service orchestration; Amdocs Charging; Amdocs eSIM Cloud that enables service providers to offer digital SIM (eSIM); Amdocs MarketONE, a based Software-as-a-Service (SaaS)-based platform that includes pre-integrated digital services, ranging from media, gaming, eLearning, sports and retail to security, and business services; and Amdocs connectX, a cloud-native telco-in-a-box software-as-a-service platform for digital telecom brands, as well as Amdocs CatalogONE that spans the entire CES25 suite and combines embedded business intelligence with telecom-specific GenAI agents. Further, the company provides consulting, experience design, data, cloud, network services, delivery, quality engineering, operations, systems integration, and content services to various platforms and technologies; maintenance, enhancement design and development, and operational support services; network deployment and optimization services; and managed services, including AI and related tools, predictive analytics, and robotic process automation, as well as quality engineering, mobile network, cloud, and professional services. Amdocs Limited was founded in 1982 and is headquartered in Saint Louis, Missouri.

Stock analysis

Amdocs Ltd (DOX) currently trades at $58.36, while our model-based Fair Value estimate is $119.31, implying the stock looks roughly 51.1% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $119.31 per share, and 20 of the 25 models we run sit above the $58.36 price.

Bear case: the Asset-Based group reads lowest at $21.64, and 5 of the 25 models stay below the price. Evidence for this calculation is high.

Scenario range: $79.30 (bear) to $155.10 (bull), the price of $58.36 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 75/100 (high quality), in the Technology sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Amdocs Ltd reported revenue of $4.5B in FY2025 versus $4.3B in FY2021, a compound +1.4%/yr. Reported net income was $565M in FY2025, compounding −4.8%/yr from FY2021.

Key figures

Market cap $6.5B · P/E ratio 11.6 · P/S ratio 1.45 · EPS (TTM) $5.01 · Dividend yield 3.7% · Net margin 12.5% · Return on equity 15.9% · Return on assets (EBIT) 10.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (medium confidence).

What moves the price

The share trades about 30% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Technology peers we cover trades at −19% fair-value upside, at 104%, DOX screens cheaper than that median.

Fair Value models

Bear $79.30 Fair Value $119.31 Bull $155.10
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($2.81 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $62.30 $89.88 $127.74 80
Growth DCF $63.92 $89.29 $122.56 79
Owner Earnings $63.36 $91.39 $129.86 77
All 25 models by family
DCF Models
FCF DCF $62.30 $89.88 $127.74 80
Owner Earnings $63.36 $91.39 $129.86 77
5Y Revenue Exit $62.84 $97.42 $140.05 72
5Y EBITDA Exit $92.33 $150.02 $214.84 75
5Y P/E Exit $82.57 $132.61 $182.68 71
10Y Revenue Exit $60.07 $90.46 $128.18 67
10Y EBITDA Exit $80.05 $125.28 $181.61 68
10Y P/E Exit $74.08 $113.75 $158.63 64
Earnings-Based
Graham-Dodd $36.17 $86.75 $111.95 65
PEG = 1.0 $15.23 $21.76 $28.28 57
EPV $56.73 $66.16 $74.31 74
Dividend Discount
Gordon GGM $18.56 $31.84 $47.53 67
DDM Multi-Stage $18.56 $27.23 $36.37 67
Multiples
P/E Multiple $111.70 $148.94 $186.17 63
P/S Multiple $67.82 $90.43 $113.03 58
P/B Multiple $67.82 $90.43 $113.03 55
EV/EBIT $136.57 $183.10 $229.64 66
EV/EBITDA $126.52 $169.70 $212.89 67
EV/Revenue $67.54 $97.79 $128.04 53
Asset-Based
NCAV (Graham) $16.15 $21.64 $32.30 54
Growth DCF
Growth DCF $63.92 $89.29 $122.56 79
Rev-Margin DCF $62.84 $98.06 $135.99 73
Economic Profit
Residual Income $33.75 $43.58 $113.23 68
ROIC Compounder $59.16 $72.73 $87.39 72
Growth Earnings
Growth-Adj P/E $83.52 $119.31 $155.10 67

Open the full fair value analysis →

Notify me when DOX reaches fair value

Put DOX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 75/100

Of which business quality 72 · Market factors (momentum, volatility) 44

Profitability 55
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Cashflow 67
Earnings quality: real cash, not paper profit
Fin. Strength 78
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 84
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
Start year 2020 (pandemic). Over 10 years: +2.2% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+10.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.0%
Dividend (yield on the price)3.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6% vs 6%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 18%
Start year 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −6.8% a year for the price and +0.8% for the forecasts.
Forecast 2026 (sales)+3.4%
Forecast 2027 (sales)+3.4%
Projected 2028 (sales)+3.3%
Projected 2029 (sales)+3.1%
Projected 2030 (sales)+2.9%

Watch DOX, get fair value alerts →

Compare Amdocs Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Infrastructure · 377 stocks

Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 75 · Top 25%
Fair Value upside +104% · Top 25%
Profitability
Return on equity (TTM) 16% · Above median
Return on assets 8% · Top 25%
Net margin (TTM) 12% · Above median
Operating margin (TTM) 16% · Top 25%
Growth and dividend
Revenue growth 4% · Below median
Dividend yield (TTM) 3.7% · Top 25%
Balance sheet
Debt / equity 0.19× · Above median

Valuation Multiplesvs Software - Infrastructure median · lower = cheaper

P/E (TTM) 11.6× · Cheapest 25%
P/B 1.90× · Cheaper than median
P/S (TTM) 1.41× · Cheaper than median
P/FCF 10.1× · Pricier than median
EV/EBITDA 6.7× · Cheapest 25%
PEG 0.69× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 18
FUTURE (revenue growth)20 · sector 49
PAST (return on equity)63 · sector 19
HEALTH (low debt)91 · sector 97
DIVIDEND (yield)74 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Software - Infrastructure stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Microsoft Corporation MSFT $498.00 $547.80 +10%
Oracle Corporation ORCL $149.20 $117.84 −21%
Palantir Technologies Inc PLTR $184.99 $43.02 −77%
Palo Alto Networks, Inc PANW $374.57 $114.50 −69%
CrowdStrike Holdings CRWD $250.06 $35.15 −86%
Fortinet, Inc FTNT $174.26 $164.92 −5%
Synopsys, Inc SNPS $409.24 $250.04 −39%
Block, Inc XYZ $77.53 $101.29 +31%
CoreWeave, Inc CRWV $86.76 $71.79 −17%
NetApp, Inc NTAP $192.91 $157.18 −19%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amdocs Ltd · Fair Value
$119.31 +51%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Amdocs Ltd Fair Value". https://www.fairvalue-calculator.com/stock/DOX

Frequently asked questions

Is Amdocs Ltd (DOX) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $119.31 versus a price of $58.36, about +104% upside (undervalued).
What is the fair value of DOX?
Our model-based fair value for Amdocs Ltd is $119.31 (as of Sep 23, 2026), built from audited fundamentals. The current price: $58.36.
What is the quality score of DOX?
Amdocs Ltd has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amdocs Ltd (DOX)?
Our model-based price target is the fair value of $119.31 (as of Sep 23, 2026) from 25 valuation models. Cautious scenario $79.30, optimistic scenario $155.10. It is a calculation from audited fundamentals, not an analyst target.
What is the Amdocs Ltd stock forecast for 2026?
Our models put fair value at $119.31, about +104% upside versus a price of $58.36 (undervalued). Cautious scenario $79.30, optimistic scenario $155.10. The calculation is refreshed regularly with new filings.
What is the revenue of Amdocs Ltd (DOX)?
Amdocs Ltd reported trailing-twelve-month revenue of about $4.6B (latest available figure, as of Sep 23, 2026).
Does Amdocs Ltd pay a dividend?
Amdocs Ltd currently shows a dividend yield of about 3.68% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Amdocs Ltd (DOX)?
For today's price to be fair in a discounted-cash-flow model, Amdocs Ltd would have to grow free cash flow by -4.5 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.7 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of DOX use?
Our models discount Amdocs Ltd at 8.5 %: a base by market capitalisation (mid), damped by beta 0.43, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Amdocs Ltd that is -4.5 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Amdocs Ltd (DOX) delivered so far?
Over the past 5 years revenue at Amdocs Ltd grew +1.7 % a year. The price currently implies -4.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Amdocs Ltd (DOX) growing?
The median revenue growth in the sector is +8.2 % a year. That is the yardstick for the growth priced into Amdocs Ltd (-4.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Amdocs Ltd (DOX)?
The free-cash-flow yield on the price is 9.89 %: that much free cash flow Amdocs Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Amdocs Ltd (DOX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amdocs Ltd it is $119.31 per share (as of Sep 23, 2026), against a price of $58.36. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Amdocs Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, DOX trades below its calculated fair value: price $58.36, fair value $119.31, a gap of about +104% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DOX?
No. The price is what the market pays today ($58.36); the fair value is what the company's own numbers justify ($119.31). For Amdocs Ltd the two are $60.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amdocs Ltd worth?
The market values Amdocs Ltd at about $6.5B (market capitalisation, as of Sep 23, 2026). Per share that is $58.36; our models calculate a fair value of $119.31 per share.
What do the bullish and bearish scenarios say about DOX?
Our models span a range for Amdocs Ltd: cautious scenario $79.30, base $119.31, optimistic $155.10 per share (as of Sep 23, 2026, price $58.36). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DOX?
Amdocs Ltd trades at a price-to-earnings ratio of 11.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $119.31 is built from several models across several years. Other multiples: PEG 0.7, P/B 1.9, P/S 1.4, EV/EBITDA 6.7.
What is the PEG ratio of DOX?
The PEG ratio of Amdocs Ltd is 0.69 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Amdocs Ltd (DOX)?
Balance-sheet figures for Amdocs Ltd (as of Sep 23, 2026): return on equity 15.9%, debt of 0.19 per unit of equity. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is DOX from its 52-week high?
Amdocs Ltd trades at $58.36, about 30% below its 52-week high of $83.26 and 18% above the low of $49.32 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $119.31 is for.
Which stocks are comparable to Amdocs Ltd?
From the same area (Technology) we also value Microsoft Corporation, Oracle Corporation, Palantir Technologies Inc, Palo Alto Networks, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amdocs Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price $58.36, calculated fair value $119.31 (+104%), Quality Score 75/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DOX calculated?
We run Amdocs Ltd through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $119.31, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Amdocs Ltd currently trades 104 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amdocs Ltd (DOX)?
The closing price on Sep 23, 2026 was $58.36. Our model-based fair value is $119.31, about +104% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amdocs Ltd right now?
The rarer combination: high quality (75/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($79.30). The market is more pessimistic than our downside scenario. A fairly wide model range ($79.30 to $155.10) leaves room in how you read the outcome.
Where does the earnings growth of Amdocs Ltd (DOX) come from?
Earnings per share at Amdocs Ltd grew +6.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.8 %, EBIT margin +0.7 %, tax rate −0.3 %, residual (interest, one-offs) −1.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Amdocs Ltd

How large is the market capitalisation of Amdocs Ltd (DOX)?
The market capitalisation of Amdocs Ltd is $6.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amdocs Ltd (DOX)?
The price-to-sales ratio of Amdocs Ltd is 1.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Amdocs Ltd (DOX)?
Earnings per share at Amdocs Ltd are $5.01 (price ÷ EPS = P/E 11.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Amdocs Ltd (DOX)?
The dividend yield of Amdocs Ltd is 3.7% (payout 42.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Amdocs Ltd (DOX)?
The net margin of Amdocs Ltd is 12.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Amdocs Ltd (DOX)?
The return on equity (ROE) of Amdocs Ltd is 15.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amdocs Ltd (DOX)?
On an EBIT basis the return on assets of Amdocs Ltd is 10.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Amdocs Ltd (DOX)?
The operating margin of Amdocs Ltd is 16.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Amdocs Ltd (DOX)?
Revenue at Amdocs Ltd is growing +3.9% versus a year earlier (3y avg −0.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Amdocs Ltd (DOX)?
Earnings per share at Amdocs Ltd are growing −11.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Amdocs Ltd (DOX) carry?
The net debt of Amdocs Ltd is $501M (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Amdocs Ltd in the live analysis

One click puts Amdocs Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.